The drug combination of ledipasvir and sofosbuvir (trade name Harvoni) has been available since November 2014 for the treatment of chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care ...
Mar 9, 2015
0
7
The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Dec 10, 2014
0
0
Is a violent criminal born that way, or shaped by childhood experiences and circumstances?
Oct 28, 2014
7
0
Two new pill-only regimens that rapidly cure most patients with genotype 1 hepatitis C (HCV) infection could soon be widely prescribed across Europe. Two recently-published studies1,2 confirmed the efficacy and safety of ...
Oct 17, 2014
0
0
Cerebral spinal fluid (CSF) levels of β-amyloid 42(Aβ42) are associated with the diagnosis of Alzheimer's disease (AD) and (Aβ) accumulation in the brain independent of apolipoprotein E (APOE) gene makeup.
Aug 27, 2014
0
0
In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal ...
Jul 28, 2014
0
0
The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around ...
Jul 28, 2014
0
0
A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.
Jul 19, 2014
0
0
(HealthDay)—Genetic mutation causing interference with encoding of hormone-sensitive lipase (HSL) results in susceptibility to metabolic disorders, according to research published online May 21 in the New England Journal ...
May 28, 2014
0
0
Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ...
Apr 12, 2014
0
0
